{
    "organizations": [],
    "uuid": "ef87df7a96e93762826ff3914152fa4e8b84d982",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-promore-oct-dec-net-sales-amounted/brief-promore-oct-dec-net-sales-amounted-to-sek-0-6-mln-idUSFWN1PW0OX",
    "ord_in_thread": 0,
    "title": "BRIEF-Promore Oct-Dec Net Sales Amounted To SEK 0.6 MLN",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 6 (Reuters) - PROMORE PHARMA AB:\n* ‍OCTOBER TO DECEMBER NET SALES AMOUNTED TO MSEK 0.6 (0)​ * OCT-DEC OPERATING LOSS FOR PERIOD WAS 10.6 (LOSS 3.6) MSEK\n* “‍FOR 2018 OUR MAIN OPERATIONAL GOALS ARE TO CONTINUE PUSHING OUR MAIN PROJECTS FORWARD BY START RECRUITMENT IN CLINICAL TRIALS OF PXL01 AND LL-37”​\n* OCT-DEC NET LOSS WAS 11.0 (LOSS 2.4) MSEK, CORRESPONDING TO A LOSS PER SHARE OF SEK 0.54 (LOSS 0.18) Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-06T22:51:00.000+02:00",
    "crawled": "2018-02-07T21:59:22.013+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "promore",
        "pharma",
        "ab",
        "december",
        "net",
        "sale",
        "amounted",
        "msek",
        "operating",
        "loss",
        "period",
        "loss",
        "msek",
        "main",
        "operational",
        "goal",
        "continue",
        "pushing",
        "main",
        "project",
        "forward",
        "start",
        "recruitment",
        "clinical",
        "trial",
        "pxl01",
        "net",
        "loss",
        "loss",
        "msek",
        "corresponding",
        "loss",
        "per",
        "share",
        "sek",
        "loss",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}